Lee Hambright
Stock Analyst at Bernstein
(4.19)
# 481
Out of 5,006 analysts
26
Total ratings
80%
Success rate
9.86%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Outperform | $97 → $98 | $97.70 | +0.31% | 3 | Aug 20, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $138 → $144 | $134.59 | +6.99% | 5 | Apr 17, 2025 | |
| PODD Insulet | Initiates: Outperform | $300 | $309.12 | -2.95% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $14.71 | +185.52% | 1 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Outperform | $82 → $86 | $67.05 | +28.26% | 2 | Oct 25, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $97.32 | +2.75% | 1 | Oct 24, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $350 → $365 | $452.35 | -19.31% | 2 | May 31, 2023 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $136 → $152 | $100.78 | +50.82% | 1 | May 3, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $183 | $188.64 | -2.99% | 4 | Mar 16, 2022 | |
| SYK Stryker | Upgrades: Outperform | $288 → $295 | $370.50 | -20.38% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $77.07 | +75.17% | 3 | Mar 16, 2022 |
Medtronic
Aug 20, 2025
Maintains: Outperform
Price Target: $97 → $98
Current: $97.70
Upside: +0.31%
Abbott Laboratories
Apr 17, 2025
Maintains: Outperform
Price Target: $138 → $144
Current: $134.59
Upside: +6.99%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $309.12
Upside: -2.95%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $14.71
Upside: +185.52%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $82 → $86
Current: $67.05
Upside: +28.26%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $97.32
Upside: +2.75%
Intuitive Surgical
May 31, 2023
Maintains: Outperform
Price Target: $350 → $365
Current: $452.35
Upside: -19.31%
Zimmer Biomet Holdings
May 3, 2023
Maintains: Market Perform
Price Target: $136 → $152
Current: $100.78
Upside: +50.82%
Johnson & Johnson
Mar 16, 2022
Downgrades: Market Perform
Price Target: $183
Current: $188.64
Upside: -2.99%
Stryker
Mar 16, 2022
Upgrades: Outperform
Price Target: $288 → $295
Current: $370.50
Upside: -20.38%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $77.07
Upside: +75.17%